Having met the primary endpoint in its OPTIMIZE-1 phase II trial with mitazalimab in pancreatic cancer, Alligator Bioscience can now start preparing for phase III. The company hosted a KOL webinar to explain the results in detail. BioStock spoke with Alligator's CMO Sumeet Ambarkhane to learn more.

Read the interview with Sumeet Ambarkhane at biostock.se:

https://www.biostock.se/en/2024/02/alligator-prepares-for-phase-iii-with-cd40-agonist/

This is a press release from BioStock - Connecting Innovation & Capital. https://www.biostock.se/en/

https://news.cision.com/alligator-bioscience/r/biostock--alligator-prepares-for-phase-iii-with-cd40-agonist,c3929807

(c) 2024 Cision. All rights reserved., source Press Releases - English